About Me
Dr. Gamis is a board certified Pediatric Hematologist/Oncologist. He also trained as an Epidemiologist receiving an MPH in 1991 as a foundation for clinical trial development. Locally, as the Director of the Children's Mercy Cancer Center, Dr. Gamis oversee all clinical and research activities related to cancer care and successfully oversaw the program's expansion, program development and ultimately consortium institutional partnership with the NCI-designated University of Kansas Cancer Center. Dr. Gamis has been active in AML research activities in the Children's Oncology Group since 1993, first serving on several COG clinical trial committees (AML, Neuroblastoma, Hodgkin’s, Stem Cell Transplant, Epidemiology, & Supportive Care/Nursing), then chairing two large clinical trials. The first was the phase III trial COG A2971 - Treatment of Children with Down’s Syndrome and AML, MDS, and Transient Myeloproliferative Disorder, from 1996-2004.This was followed by a second national Phase III trial, COG-AAML0531- Phase III Randomized Trial of Gemtuzumab Combined with Conventional Chemotherapy for de novo Acute Myeloid Leukemia in Children, from 2004 until the present. Dr. Gamis has served as a member of the COG Myeloid Scientific Disease Committee since 1996 and served as Chair of the committee from 2007-2013 overseeing all aspects of Myeloid Leukemia research (design, implementation, analysis, and strategic planning) during which time we designed and developed numerous clinical trials in childhood AML. He has also served on the COG Epidemiology Steering Committee from 1992-1995 and the COG Stem Cell Transplant Steering Committee from 2002 to 2010. He was a founding member of the Pediatric Blood and Marrow Transplant Consortium beginning in 1992 ultimately serving as its Chair from 1999-2004 during which time he led the successful attainment of the UO1 NHLBI grant as an original PI of a clinical core center of the Bone Marrow Transplant Clinical Trials Network (BMT CTN). During this time he successfully joined the PBMTC with the COG through the NIH grant BAA-RM-04-23 grant, Re-engineering the Clinical Research Enterprise: Feasibility of Integrating and Expanding Clinical Research Networks, from 2004-2008.